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Abstract: With an increased understanding of the tumor biology of squamous cell carcinoma of the
head and neck (SCCHN), targeted therapies have found their way into the clinical treatment routines
against this entity. Nevertheless, to date platinum-based cytostatic agents remain the first line choice
and targeting the epidermal growth factor-receptor (EGFR) with combined cetuximab and radiation
therapy remains the only targeted therapy approved in the curative setting. Investigation of immune
checkpoint inhibitors (ICI), such as antibodies targeting programmed cell death protein 1 (PD-1) and
its ligand PD-L1, resulted in a change of paradigms in oncology and in the first approval of new
drugs for treating SCCHN. Nivolumab and pembrolizumab, two anti-PD-1 antibodies, were the first
agents shown to improve overall survival for patients with metastatic/recurrent tumors in recent
years. Currently, several clinical trials investigate the role of ICI in different therapeutic settings.
A robust set of biomarkers will be an inevitable tool for future individualized treatment approaches
including radiation dose de-escalation and escalation strategies. This review aims to summarize
achieved goals, the current status and future perspectives regarding targeted therapies and ICI in the
management of SCCHN.
Keywords: immune-checkpoint inhibition; targeted therapy; head and neck cancer; EGFR; mTOR; TKI
1. Introduction
Squamous cell carcinoma of the head and neck (SCCHN) is diagnosed in approximately
500,000 patients per year worldwide with rising incidence [1], mainly attributed to younger individuals
with Human-Papilloma-Virus (HPV)-positive tumors and to an increasing number of elderly patients
due to an improved life expectancy [2]. Standard treatment for early stage tumors consists of surgery
or radiotherapy (RT), and for locoregionally advanced tumors of radical surgery with subsequent
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adjuvant RT/chemoradiotherapy (CRT) or primary CRT [3]. Despite advances in CRT, locoregional
recurrences occur in up to 40% and distant metastases in approximately 25% of all cases with locally
advanced (LA) SCCHN [4–6]. To date, platinum-based chemotherapy remains first line systemic
therapy both in the curative and recurrent and/or metastatic (R/M) setting. The approval of the
epidermal growth factor-receptor (EGFR) antagonist cetuximab introduced the first targeted therapy
in SCCHN showing increased locoregional control when compared to RT alone [7] and improved
outcome when combined with chemotherapy in the palliative situation [8].
Interestingly, the immune system appears to affect treatment response in the context of RT/CRT [9].
Accumulating data regarding the interplay between tumor/microenvironment and the immune contexture,
as well as mechanisms underlying immune-checkpoint pathway regulation, suggest that targeted therapies
can promote anti-tumor immunity and mediate durable cancer regression [9]. RT can modulate these
effects via “immune vaccination” (e.g., through up-regulation of MHC class I molecules) and enhanced
antigen presentation on the surface of tumor and dendritic cells (DC), which may also partly explain
the abscopal effect occasionally seen in the clinical setting [10]. These observations, together with the
encouraging results observed for other malignant diseases [11,12] led to an abundance of clinical trials
aiming to modulate immune response for SCCHN, especially regarding immune-checkpoint inhibition
(ICI) [13–15].
This review discusses planned, recruiting and completed clinical trials assessing immuno- and
targeted therapies in the primary and R/M setting for SCCHN. Included studies are prospective
clinical landmark trials, which provided evidence for current treatment strategies, or major ongoing
trials (cited according to their ClinicalTrials.gov registry number NCT). Trials were identified at
www.ClinicalTrials.gov, at PubMed database or from presentations at corresponding societal meetings.
2. Immune-Checkpoint Inhibition in SCCHN: Mode of Action
2.1. PD-1/PD-L1 Axis and CTLA4 Blockade
The blockade of the PD-1/PD-L1 interaction and the cytotoxic T-lymphocyte antigen 4 (CTLA-4)
via various antibodies has emerged as a powerful tool in anticancer therapy with the potential to
reverse cancer-mediated immunosuppression. Among the different T-cell inhibitory and co-inhibitory
pathways, those two have been best-characterized within recent years [16].
PD-1 was first described in 1992 and its role as an immune checkpoint has been unraveled in the
following years [16,17]. Aside from T-cells, PD-1 is also expressed by natural killer (NK) cells, B-cells
regulatory T-cells and macrophages. PD-1 is a transmembrane receptor inhibiting the T-cell receptor
(TCR) downstream pathway via tyrosine phosphatase SHP-2 activity. Regarding T-cells it affects
activation, exhaustion, immune tolerance and inflammation [18]. Activation of PD-1 occurs via binding
of its two ligands PD-L1 (expressed by antigen-presenting cells (APC) and somatic cells) and PD-L2
(expressed by macrophages and DC). Both ligands can be overexpressed in SCCHN and are naturally
induced by pro-inflammatory signals, protecting self-tissue from an excessive immune response [16,19]
(Figure 1). Several antibodies against PD-1 (pembrolizumab, nivolumab) and PD-L1 (atezolizumab,
durvalumab, avelumab) have already gained approval by the Food and Drug Administration (FDA)
for various tumor entities.
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IFN-γ—Interferon-γ, SHP2—Tyrosine phosphatase SHP-2, PD-1-Programmed cell death protein 1, 
PD-L1—Programmed cell death ligand 1. 
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ipilimumab has been tested in clinical trials since 2000 to treat patients with melanoma and ovarian 
carcinoma [23,24]. Upon co-activation of the TCR and co-stimulatory CD28 receptor, CTLA-4 is 
expressed and translocates to the cell membrane. CTLA-4 competes with CD28 for its ligands CD80 
and CD86 with a 50–2000 fold increased affinity [20]. Also, CTLA-4 can bind phosphatases to its 
intracellular part to further reduce TCR and CD28 signaling affecting both CD8+ and CD4+ T-cells 
[20,25]. Unlike PD-1, CTLA-4 is a non-redundant immune checkpoint and knock-out mice die within 
weeks due to T-cell mediated multi-organ inflammation [26,27] (Figure 2). 
 
Figure 2. Mechanism of CTLA-4 blockade. A: Co-stimulation of TCR/CD28 induces CTLA-4 receptor 
expression, B: Interaction of CTLA-4 and CD80/86 inhibits IL-2 signaling, promotes apoptosis and the 
secretion of immunosuppressive i cytokines, such as TGFβ, C: CTLA-4 receptor blockade by 
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2—Interleukin-2, TGFβ—Transforming Growth Factor beta. 
Figure 1. echanism of PD-1/PD-L1 blockade. (A): IFN-γ release upon TCR activation induces
PD-L1 expression, (B): Interaction of PD-1/PD-L1 inhibits TCR signaling via SHP2, (C): Blockade
of the PD-1/PD-L1 axis via atezolizumab, durvalumab, avelumab, nivolumab or pembrolizumab
enhances T cell activation and proliferation; Abbreviations: IS—Intracellular space, CM—Cell
membrane, ES—Extracellular space, TCR—T-cell receptor, MHC—Major histocompatibility complex
I, AG—Antigen, IFN-γ—Interferon-γ, SHP2—Tyrosine phosphatase SHP-2, PD-1-Programmed cell
death protein 1, PD-L1—Programmed cell death ligand 1.
CTLA-4 is a potent inhibitor of T-cell proliferation and activation [20–22], and its blockade via
ipilimumab has been tested in clinical trials since 2000 t treat patients with melanoma and ovarian
carcinoma [23,24]. Upon co-activation of th TCR and co-s imulatory CD28 receptor, CTLA-4 is
expressed and translocates to the cell membrane. CTLA-4 competes with CD28 for its ligands CD80 and
CD86 with a 50–2000 fold increased affinity [20]. Also, CTLA-4 can bind phosphatases to its intracellular
part to further reduce TCR and CD28 signaling affecting both CD8+ and CD4+ T-cells [20,25]. Unlike
PD-1, CTLA-4 is a non-redundant immune checkpoint and knock-out mice die within weeks due to
T-cell mediated multi-organ inflammation [26,27] (Figure 2).
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Figure 2. Mechanism of TL -4 blockade. (A): Co-stimulation of TCR/CD28 induces CTLA-4
receptor expression, (B): Interaction of CTLA-4 and CD80/86 inhibits IL-2 signaling, promotes
apoptosis and the secretion of immunosuppressive i cytokines, such as TGFβ, (C): CTLA-4
receptor blockade by ipilimumab or tremelimumab enhances T cell activation and proliferation;
Abbreviations: IS—Intracellular space, CM—Cell membrane, ES—Extracellular space, TCR—T-cell
receptor, MHC—Major histocompatibility complex I, AG—Antigen, CTLA-4—Cytotoxic T-lymphocyte
antigen 4, IL-2—Interleukin-2, TGFβ—Transforming Growth Factor beta.
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Radiotherapy modulates the host immune system in various ways such as an upregulation of MHC
(major histocompatibility complex) class I molecules enhancing local CD8+ T-cell effects, intensified
expression of calreticulin and other prophagocytic signals and upregulation of PD-L1 on the tumor
cells surface [10]. This local tumor immune-vaccination by RT also promotes the systemic abscopal
effect occasionally seen in the clinical setting [28]. The host immune response against the tumor
prompted by RT could be enforced by either generally boosted immune response (anti-CLTA-4) or
reversed immunoediting (e.g., anti-PD-1/PD-L1) [29,30]. Also, cytotoxic chemotherapy has important
immunomodulatory activity and its effects cannot be reduced to immunosuppression via myelotoxicity.
For example, platinum-based drugs enhance T-cell activation by dendritic cells and docetaxel decreases
numbers of regulatory T-cells [31]. In line with that, the phase III randomized, Keynote-048 trial [15]
has evaluated this concept (pembrolizumab + chemotherapy) and proven its enhanced efficacy in the
clinical setting for head and neck cancer (see also Section 2.2.1).
A robust set of biomarkers will be of great importance to select patients for targeted therapies and
combined approaches. Emerging predictive biomarkers for PD-1/PD-L1 blockade are micro-satellite
instability (MSI-H), tumor mutational burden (TMB) and T cell-inflamed gene expression profile
(GEP) [32]. So far, data on safety and efficacy of combined RT/CRT and ICI are mostly of retrospective
nature [33].
2.2. Immune-Checkpoint Inhibition in the Recurrent/Metastatic Situation
2.2.1. PD-1 Inhibition
For R/M SCCHN several immunoregulatory receptors and combined treatments are currently
under investigation [34,35]. Pembrolizumab, an IgG4 PD-1 monoclonal antibody (MK-3475, Merck
Sharp & Dohme), was introduced in 2013 within the Keynote-012 trial recruiting patients with different
solid malignancies. Sixty patients with R/M SCCHN (+/− prior treatment) with any detectable PD-L1
expression (≥1%) on tumor cells/stroma and Eastern Cooperative Oncology Group (ECOG) performance
status (PS) 0–1 were treated with pembrolizumab monotherapy and received 10 mg/kg bodyweight
(BW) every two weeks (q2w). In total, 17% of the patients experienced grade 3–4 drug-related adverse
events (AE, AEs covering pneumonitis, colitis, hepatitis, adrenal insufficiency, diabetes mellitus, and
skin toxicities). Overall response rate (ORR) was 18% after 14 months of median follow-up [36].
The expansion cohort of the Keynote-012 trial comprised further 132 enrolled patients, regardless of
their PD-L1 expression status treated with an adjusted dosage of pembrolizumab (200 mg fixed-dose
(FD) q3w). Treatment-related grade 3–4 AEs occurred in 9% and the ORR after a median follow-up of
9 months was 18% and equal to that of the first phase. [37]. Pooled analysis revealed treatment-related
AEs of any grade and grade 3–4 in 64% and 13% of the patients, respectively, but no treatment-related
deaths occurred [38].
Amongst other early studies, the ECHO-202/Keynote-037 phase I/II trial enrolled patients with
R/M disease with progress to prior therapy with different tumor entities, but only 2 patients with R/M
SCCHN. Phase I results were published recently indicating that epacadostat + pembrolizumab were
well tolerated and showed antitumor activity in different advanced solid tumors [39]. By contrast, the
Keynote-669/ECHO-304 phase III trial testing the combination (pembrolizumab with the indoleamine
2,3-dioxygenase 1 enzyme inhibitor vs. EXTREME regimen) was closed after recruiting only 89 of
originally 625 planned patients and no report has been published yet [40].
In the Keynote-055 phase II trial, 171 patients with disease progression within 6 months of
platinum and cetuximab therapy were treated by pembrolizumab: 75% of the patients previously
already had ≥2 lines of therapy for R/M disease. Combined positive score (number of PD-L1 stained
cells including tumor cells, lymphocytes and macrophages/total number of viable tumor cells) ×100,
CPS) for PD-L1 of ≥1 was found in 82% of the cases. ORR was 16%, median progression-free survival
(PFS) was 2.1 months and OS was 8 months and such comparable to chemotherapy for this advanced
situation [41].
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Following these early data, Cohen et al. [14] conducted a multicentric phase III trial (Keynote-040)
and randomized 495 R/M SCCHN patients progressing during or after platinum-based therapy to receive
pembrolizumab or standard of care (SOC) chemotherapy consisting of either methotrexate, docetaxel
or cetuximab. The group demonstrated that median OS was 8.4 months for the pembrolizumab cohort
and 6.9 months for the SOC cohort (hazard ratio (HR) 0.80, 95% confidence interval (CI), 0.65–0.98,
nominal p = 0.0161) and grade ≥3 AEs 13% vs. 36% in favor of the immunotherapy cohort. As such, the
new substance proved to be both more effective and better tolerated than other monotherapy-regimens.
Furthermore, in the tumor proportion score (TPS: Number of PD-L1 stained tumor cells/Total number
of viable tumor cells) ×100) ≥50% subgroup (n = 129), PFS and OS were significantly prolonged through
immunotherapy (PFS: HR 0.58, 95% CI, 0.39–0.86, p = 0.003; OS: HR 0.53, 95% CI, 0.35–0.81, p = 0.001).
ORRs were 26.6% in the pembrolizumab group and 9.2% in the SOC group [42,43]. Despite initially
missing the pre-specified primary endpoint (OS in the intention-to-treat cohort) the Keynote-040 trial
led to the FDA approval (2016) of pembrolizumab for R/M SCCHN patients with a PD-L1 TPS of ≥50%
after prior platinum-based therapy.
In a next step, results of the second interim analysis of the Keynote-048 phase III randomized trial
were presented at the annual meeting of the European Society for Medical Oncology (ESMO), 2018 in
Munich, Germany [15]. A total of 825 patients with R/M SCCHN with ECOG PS 0–1 were randomized
(1:1:1) to receive first line treatment consisting of either pembrolizumab alone, pembrolizumab +
cis-/carboplatin + 5-fluorouracil (5-FU), or cis-/carboplatin + 5-FU and cetuximab (according to the
EXTREME protocol [8]). The comparison of pembrolizumab alone versus EXTREME for the CPS ≥ 1
subgroup (n = 512) showed a higher median OS of 12.3 vs. 10.3 months (HR 0.78, 95% CI, 0.64–0.96,
p = 0.0086), a lower ORR of 19.1% vs. 34.9% and a higher median duration of response (DOR) of 20.9
vs. 4.5 months, respectively for the pembrolizumab cohort. Treatment-related AEs grade 3–5 occurred
in 16.7% and 69.0% in favor of the immunotherapy. For the CPS ≥ 20 subgroup (n = 255) median
OS was prolonged to 14.9 vs. 10.7 months (HR 0.61, 95% CI, 0.45–0.83, p < 0.001). The comparison
of pembrolizumab + chemotherapy vs. EXTREME showed a significant prolongation of OS for the
combination of chemo- and immune therapy (13.0 vs. 10.7 months, HR 0.77, 95% CI, 0.63–0.93, p= 0.003).
This trial is the first phase III comparison of immunotherapy and platinum-based chemotherapy and
establishes pembrolizumab as first-line therapy for R/M SCCHN.
Recent studies assessing pembrolizumab for more specific indications include the ELDORANDO-trial,
an ongoing phase II prospective randomized trial testing first line pembrolizumab 200 mg q3w vs.
Methotrexate 40 mg/m2 body surface area (BSA) for elderly, frail or cisplatin ineligible patients with R/M
SCCHN. Cisplatin ineligibility is defined as EGOG PS 2 and/or impaired renal function. The primary
endpoint is one year-OS and recruitment is scheduled to be completed in 2021.
Nivolumab, another IgG4 PD-1 monoclonal antibody (BMS-936558, Bristol-Myers Squibb),
received FDA approval in 2016 for R/M SCCHN with or without PD-L1 expression based on the
results of the randomized, phase III CheckMate 141 trial by Ferris et al. [13]. In total, 361 patients
were enrolled to receive either nivolumab 3 mg/kg q2w or SOC methotrexate, docetaxel or cetuximab
(2:1 randomization). Median OS was significantly prolonged by nivolumab versus SOC (7.5 vs.
5.1 months, HR 0.70, 97.73% CI, 0.51–0.96, p = 0.01), whereas PFS was not affected. The response rate
was 13.3% for nivolumab versus 5.8% for SOC and grade 3–4 toxicities occurred in 13.3% versus 35.1%,
respectively. Toxicities included pneumonitis, dermatitis, and endocrine dysfunction. An updated
long-term follow-up analysis indicated a 24-months OS rate of 16.9% for nivolumab and 6.0% for SOC,
confirming the possibility for durable responses in a subgroup of patients, as it has been observed in
malignant melanoma [44].
2.2.2. Oligometastatic Disease
A phase II trial (NCT02684253) randomized patients with R/M SCCHN with or without prior
platinum-based therapy and at least two distinct metastatic lesions between nivolumab 3 mg/kg
q2w alone and nivolumab with stereotactic body radiotherapy applied to one lesion (SBRT, 9 Gray
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×3). Primary outcome measure was an increase in the ORR of the non-irradiated lesion (abscopal
effect) from 15% to 45%. However, ORR did not differ significantly between the two arms (30.8% for
nivolumab mono, 25.9% for nivolumab + SBRT) [45].
The ongoing IMPORTANCE phase II trial randomizes patients (ECOG PS 0–1) with at least
two distinct R/M lesions of SCCHN between pembrolizumab mono and pembrolizumab plus RT to
1–3 lesions. In case of CPS ≥ 1, pembrolizumab usage is allowed without prior platinum-based therapy.
The main objective is to test the effect of local RT on systemic response to pembrolizumab.
The trial will assess the effect of local radiotherapy in addition to pembrolizumab. Recruitment
started in 2018 and is estimated to be completed within 24 months with a total number of 130 patients.
2.2.3. Combined PD-1 and CTLA-4 Inhibition
In an effort to intensify immune response, the recruiting Checkmate 714 double-blind, randomized
(2:1) phase II trial applies first/second line nivolumab (q2w) and ipilimumab (IgG1 CTLA-4 monoclonal
antibody, BMS-734016, Bristol-Myers Squibb, q6w) vs. nivolumab (q2w) and placebo (q6w) to R/M
SCCHN patients. Primary outcome measure is ORR according to RECIST v1.1 [46]. The CheckMate
651 trial examines the efficacy of combined therapy with nivolumab and ipilimumab for first line
R/M SCCHN treatment [47]. Enrollment started in 2017 and completion is estimated to be reached in
2020. Patients are randomized 1:1 between immunotherapy and the EXTREME protocol. Following a
sequential strategy, OPTIM (NCT03620123) is an ongoing phase II trial delivering nivolumab for R/M
SCCHN after prior platinum-based therapy, where in case of progression patients are randomized (1:1)
to either receive nivolumab and ipilimumab (1 mg/kg BW q6w) or docetaxel (75 mg/m2 BSA q3w).
Recruitment started in 2018 and estimated primary completion is awaited to be in 2022.
2.2.4. PD-L1 Inhibition
Durvalumab (IgG1 PD-L1 monoclonal antibody, MEDI4736, AstraZeneca) has been approved
for the treatment of locally-advanced non-small cell lung carcinoma after CRT [48]. No approval for
SCCHN does exist so far, but several clinical trials were completed or are still ongoing. An initial
phase I/II trial (Study 1108) enrolled 62 patients with R/M SCCHN in a basket trial design of different
solid tumor entities, applying durvalumab (10 mg/kg q2w) for 12 months. The 12-month OS was 42%,
ORR 11% and AEs ≥grade 3 occurred in 8% of the patients, who had a median of 3 prior systemic
treatments [49,50]. To further investigate durvalumab in R/M SCCHN after prior platinum-based
therapy, two phase II trials, HAWK and CONDOR, were conducted [51,52]. The HAWK single-arm
trial applied durvalumab to patients with PD-L1 positive tumors (TPS ≥ 25%). Among the 111 patients,
the ORR was 16.2%, median PFS and OS 2.1 and 7.1 months, respectively. Adverse events of any
grade occurred in 57.1%, and of grade ≥ 3 in 8% of the cases. On the other hand, CONDOR enrolled
patients with low/negative PD-L1 tumor expression (TPS < 25%). They were randomized in a 2:1:1
design to either receive durvalumab (20 mg/kg BW q4w) and tremelimumab (IgG2 CTLA-4 monoclonal
antibody, AstraZeneca, 1 mg/kg BW q4w) for 4 cycles followed by durvalumab (10 mg/kg BW q2w), or
durvalumab (10 mg/kg BW q2w) monotherapy, or tremelimumab (10 mg/kg BW q4w for 7 doses then
every 12 weeks for 2 doses) monotherapy. Median OS did not differ between the groups and reached
7.6 months for combined modality therapy. The ORRs were 7.8% for durvalumab + tremelimumab,
9.2% for durvalumab, and only 1.6% for tremelimumab alone, demonstrating for the first time that
CTLA-4 inhibition might contribute to enhanced toxicity and not to an improvement of response
in SCCHN.
Two randomized phase III trials utilizing durvalumab completed recruitment recently. The EAGLE
trial randomized patients 1:1:1 to receive second line durvalumab (10 mg/kg IV for up to 12 months) vs.
tremelimumab (1 mg/kg IV) plus durvalumab (20 mg/kg IV for up to 12 months) vs. SOC (cetuximab,
taxane, methotrexate, or fluoropyrimidine) [53]. In a press release by AstraZeneca from December
2018 it was stated that neither the combination of durvalumab and tremelimumab nor durvalumab
alone prolonged OS vs. SOC (primary trial endpoint) [54].
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In a similar design for platinum-eligible patients, the KESTREL trial randomized (2:1:1) to either
first line flat-doses of tremelimumab 75 mg q4w and durvalumab 1500 mg q4w vs. durvalumab 1500 mg
q4w vs. the EXTREME regimen. Primary endpoint is the efficiacy of durvalumab + tremelimumab vs.
SOC in terms of OS [55]. First results are being awaited in 2019 [54] (Table 1).
Table 1. Selected trials including immune-checkpoint inhibition for recurrent/metastatic SCCHN.
PI/Author Phase Trial/NCTNumber Trial Design
# Substance No. ofPatients‡ Status
Colevas et al. [56] Ia PCD4989gNCT01375842
single-arm,
multicentric Atezolizumab*
,† 32 complete
Seiwert et al. [36] Ib Keynote-012NCT01848834
single-arm,
multicentric Pembrolizumab
† 60 complete
Segal et al. [49] I/II Study 1108NCT01693562
single-arm,
multicentric Durvalumab
† 62 complete
Zandberg et al. [52] II HAWKNCT02207530
single-arm,
multicentric Durvalumab
† 111 complete
Siu et al. [51] II CONDORNCT02319044
randomized,
multicentric
Durvalumab + Tremelimumab†
vs. Durvalumab vs.
Tremelimumab
267 complete
Bauml et al. [41] II Keynote-055NCT02255097
single-arm,
multicentric Pembrolizumab
† 171 complete
Grünwald et al. II ELDORANDONCT03193931
randomized,
multicentric
Pembrolizumab* vs.
Methotrexate e.e. 100 recruiting
Grünwald et al. II OPTIMNCT03620123
randomized,
multicentric
Nivolumab + Ipilimumab† vs.¥
Docetaxel
e.e. 280 recruiting
Fietkau et al. II IMPORTANCENCT03386357
randomized,
multicentric Pembrolizumab
† e.e. 130 recruiting
McBride et al. [45] II NCT02684253 randomized,multicentric
Nivolumab + SBRT vs.
Nivolumab 66 complete
Haddad et al. [46] II Checkmate714NCT02823574
double-blind,
randomized,
multicentric
Nivolumab + Ipilimumab
vs, Nivolumab + Placebo e.e. 315 recruiting
Cohen et al. [14] III Keynote-040NCT02252042
randomized,
multicentric
Pembrolizumab† vs.
Methotrexate, Docetaxel or
Cetuximab
495 complete
Burtness et al. [15] III Keynote-048NCT02358031
randomized,
multicentric
Pembrolizumab* vs.
Pembrolizumab + Cisplatin +
5FU vs. EXTREME
825 recruitmentcompleted
Ferris et al. [13] III CheckMate141NCT02105636
randomized,
multicentric
Nivolumab† vs.
Methotrexate, Docetaxel or
Cetuximab
361 complete
Argiris et al. [47] III CheckMate651NCT02741570
randomized,
multicentric
Nivolumab + Ipilimumab vs.
EXTREME e.e. 490 recruiting
Seiwert et al. [55] III KESTRELNCT02551159
randomized,
multicentric
Durvalumab + Tremelimumab*
vs. Durvalumab vs. EXTREME 823
recruitment
completed
Ferris et al. [53] III EAGLENCT02369874
randomized,
multicentric
Durvalumab + Tremelimumab vs.
Durvalumab vs. Cetuximab,
Taxane, Methotrexate, or
Fluoropyrimidine
720 recruitmentcompleted
# All trials are open-labeled; * First line, † Second line or higher, ¥ Randomization after progression on Nivolumab
mono after prior platinum-based therapy, ‡ Patients with squamous cell carcinoma of the head and neck—total
number of patients in basket trials may exceed the given number; Abbreviations: PI—Principal investigator,
e.e.—Estimated enrollment, 5FU—5-fluorouracil, EXTREME—Cis-/Carboplatin + 5-fluorouracil + Cetuximab,
SBRT—Stereotactic body radiotherapy.
A comparable agent, atezolizumab (IgG1 PD-L1 monoclonal antibody, MPDL3280A, Hoffmann-La
Roche) was first applied to humans in a basket trial and administered as single agent to patients
with locally advanced or metastatic solid malignancies or hematologic malignancies (total n = 661).
Thirty-two SCCHN patients with locally advanced or metastatic disease were included, seven patients
(22%) had primary tumors and 17 (53%) had ≥ 2 prior lines of therapy. A total of four (13%) experienced
grade ≥ 3 AEs, ORR reached 22% and median OS was 6 months [56]. Based on these results, the
IMvoke010 phase III trial for the primary situation is now recruiting [57].
2.3. Immune-Checkpoint Inhibition in the Curative Setting
Several phase III clinical trials for the primary treatment of LA-SCCHN are ongoing, but none
reported definite results so far (Table 2). In this clinical scenario ICI are mostly investigated as
augmentation for the validated treatment strategies RT/CRT and surgery (e.g., 70 Gy + cisplatin +
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placebo vs. cisplatin + ICI [58]). Preliminary results from the GORTEC 2015-01 prospective, randomized
phase II trial (n = 133), which compared pembrolizumab vs. cetuximab in combination with RT
for LA SCCHN indicated that treatment completion rate did not differ between the two groups,
but ≥ grade 3 mucositis and radiodermatitis occurred significantly more often when RT was combined
with cetuximab [59]. After initial safety trials [60], the results of ongoing large phase III trials presented
below will give further important insights regarding feasibility and benefits of combined RT/CRT + ICI.
Table 2. Selected phase III clinical trials on immune-checkpoint inhibition for primary LA-SCCHN.
PI/Author Trial/NCTNumber Substance and Treatment
# Primary
Endpoint/Design
Estimated
Enrollment‡/Primary
Completion¥
Lee et al. [58]
Javelin Head and
Neck 100
NCT02952586
70Gy RT + Cisplatin + Avelumab vs.
Placebo PFS/DB
N = 640
04/2021
GORTEC [61] REACHNCT02999087
FIT: 70Gy RT + Cisplatin vs.
Cetuximab + Avelumab UNFIT: 70Gy
RT + Cetuximab vs. Cetuximab +
Avelumab
PFS/OL N = 64010/2019
GORTEC NIVOPOSTOPNCT03576417
66Gy PO RT Randomization:
Cisplatin vs. Cisplatin + Nivolumab DFS/OL
N = 484
12/2012
Busch et al. IMSTAR-HNNCT03700905
Surgery +PO RT/CRT vs. Nivolumab
+ Surgery + PO RT/CRT +
Nivolumab/Nivolumab + Ipilimumab
DFS/OL N = 27605/2024
Siu et al. [62] Keynote-412NCT03040999
70Gy RT + Cisplatin +
Pembrolizumab vs. Placebo EFS/DB
N = 780
04/2021
MSD Keynote-689NCT03765918
Pembrolizumab + Surgery + PO
RT/CRT vs. Surgery + PO RT/CRT mPR, EFS /OL
N = 600
01/2023
EORTC ADHERENCT03673735
66Gy PO RT + Cisplatin
Randomization: Nivolumab vs.
Placebo
DFS/DB N = 65007/2026
Mell et al. NRG-HN004NCT03258554
70Gy RT + Cetuximab vs.
Durvalumab DLT,PFS,OS/OL
N = 523
12/2025
Haddad et al.
[57]
IMvoke010
NCT03452137 Atezolizumab vs. Placebo EFS/DB
N = 400
08/2023
‡ Locally advanced squamous cell carcinoma of the head and neck, #All trials are open-labeled, randomized and
multicentric, ¥ Last participant who received an intervention to collect final data for the primary outcome
measure (dates according to clinicaltrials.gov accessed on 28 January 2019); Abbreviations: PI—Principal
investigator, PFS—Progression-free survival, DFS—Disease-free survival, EFS—Event-free survival, OS—Overall
survival, DLT—Dose-limiting toxicities, PO—Post-operative, RT—Radiotherapy, CRT—Chemoradiotherapy,
GORTEC—Groupe Oncologie Radiotherapie Tete Et Cou, mPR—Major pathological response, DB—Double-blind,
OL—Open-labeled, MSD—Merck Sharp & Dohme, EORTC—European Organization for Research and Treatment
of Cancer.
Lee et al. inaugurated a trial for patients receiving standard full-dose RT and cisplatin, randomized
to either receive the PD-L1 antibody avelumab (IgG1 PD-L1 monoclonal antibody, L01X-C, Pfizer,
10 mg/kg BW) or placebo according to the following regime: Day 1 of the lead-in phase; Days 8, 25,
and 39 of the CRT Phase; and q2w for 12 months during the maintenance phase. Lead-in avelumab
is supposed to induce early immune response before/during CRT. Estimated primary completion is
awaited in 2021 [58]. Another phase III trial REACH divides patients prior to randomization into fit
(cisplatin eligible, n = 420) and unfit patients (defined as cisplatin ineligible, n = 268). Standard arm
therapy comprises intensity-modulated RT (IMRT, 69.96 Gy, 33 fractions, simultaneously integrated
boost) and either cisplatin (100 mg/m2 BSA, q3w) for the fit or cetuximab (400 mg/m2 BSA loading dose
followed by 250 mg/m2 BSA q1w) for the unfit participants. Systemic therapy in the experimental arms
consists of cetuximab plus avelumab (10 mg/kg BW q2w). A successful 1st step safety analysis was
recently presented at the ASCO (American Society of Clinical Oncology) meeting 2018 [61]. Another
trial investigating nivolumab + cisplatin vs. cisplatin for platinum eligible patients and nivolumab
vs. cetuximab for platinum ineligible patients with primary IMRT 70/2 Gy was recently closed due to
slow accrual without any results being published (NCT03349710). In the Keynote-412 trial patients
with ECOG PS 0-1 are randomly assigned to receive pembrolizumab 200 mg q2w plus cisplatin-based
CRT or placebo plus cisplatin-based CRT [62]. For LA SCCHN patients ineligible for cisplatin, the
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NRG-HN004 randomizes between primary RT (70 Gy IMRT) with either cetuximab or durvalumab
(1500 mg FD q4w). The trial is actually suspended due to scheduled interim monitoring and the
planned end date was prolonged from 2022 to 2025. Finally, following a “maintenance” strategy,
another phase III trial evaluates the benefit of atezolizumab vs. placebo after definitive treatment of
LA SCCHN patients. Patients receive atezolizumab 1200 mg FD q3w for up to one year with the aim
to prevent local and distant disease recurrence [57].
In the peri-operative setting, the French NIVOPOSTOP trial aims to evaluate the benefit of adding
nivolumab to CRT for patients with LA-SCCHN and ECOG PS 0–1, who receive postoperative CRT
for R1 resection or extracapsular extension (ECE) of regional lymph node metastases. Patients are
scheduled for standard IMRT 66/2 Gy and are randomized to either cisplatin (100 mg/m2 BSA on days
1, 22, 43 of RT) vs. cisplatin plus nivolumab (360 mg FD 3 weeks before RT and on days 1, 22 and 43 of
RT). The German IMSTAR-HN trial compares neoadjuvant single time nivolumab 3 mg/kg within two
weeks before surgery followed by standard surgical tumor resection including neck dissection plus
postoperative RT/CRT with cisplatin, followed by post-adjuvant immunotherapy by either nivolumab
or nivolumab plus ipilimumab (1 mg/kg q6w). In a similar setting the Kenyote-689 trial evaluates two
cycles of pembrolizumab in the neoadjuvant setting followed by standard RT for low risk patients or
cisplatin-based CRT plus pembrolizumab for high risk patients in the experimental arm vs. standard
surgery plus postoperative RT/CRT in the control arm. This study is currently recruiting and is
expected to be completed in 2026. Furthermore, two phase III trials utilizing durvalumab are currently
launching (ADHERE) or are temporarily closed to accrual (NRG-HN004) in the primary treatment
setting: ADHERE will test SOC postoperative CRT (66/2 Gy with cisplatin) for high risk (R1/ECE,
HPV-negative) LA SCCHN together with durvalumab 1500 mg FD q4w or placebo. Recruitment is
scheduled to start in the first half of 2019.
3. Targeted Therapies for SCCHN
3.1. EGFR-Inhibition: Mode of Action
Epidermal growth factor receptor (EGFR) is a transmembrane member of the ErbB receptor tyrosine
kinase family. Following binding of one of its ligands EGF, transforming growth factor (TGF)-alpha
or amphiregulin, receptor kinase activation results in the activation of the Ras/Raf/mitogen-activated
protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/AKT and Janus kinase (JAK)/signal transducer
and activator of transcription 3 (STAT3) pathways. These pathways facilitate cell proliferation, hamper
apoptosis, promote angiogenesis, and activate invasion and metastasis [63,64] (Figure 3).
3.2. EGFR-Inhibition for SCCHN
EGFR is overexpressed in up to 90% of SCCHN and its overexpression has been shown to correlate
with impaired prognosis and radiation-resistance [64,65]. Furthermore, preclinical studies indicated
that EGFR-inhibition enhances radiation sensitivity [66].
EGFR-blockade was the first targeted therapy which was tested for treating SCCHN, combined
with either cisplatin or RT [67,68]. Prospective phase II [69–71] and randomized phase III trials [7,8,65]
led to the approval of cetuximab, a chimeric anti-EGFR-antibody for treating SCCHN both in the
primary, curative setting, combined with RT and in the R/M setting combined with chemotherapy. To
date, various chemotherapy/cetuximab combinations [8,72] remain the standard of care for the R/M
situation [73] and cetuximab was applied as monotherapy for chemotherapy ineligible patients or
combined with re-irradiation for locoregionally limited recurrent disease [74,75]. This standard is
likely to change following recent findings in the field of immunotherapy demonstrating improved
outcome of patients receiving ICI, at least when compared with cetuximab monotherapy [14]. Yet,
cetuximab concomitant to RT remains standard of care in the primary, curative setting [73,76] for
cisplatin-ineligible patients.
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Interestingly, other drugs targeting the EGF-receptor, either by the humanized antibody
panitumumab or by small molecule tyrosine-kinase inhibition failed to show any clinical benefit.
The CONCERT-1 and 2 trials, two parallel conducted prospective, randomized phase II trials, failed
to show any benefit either by triple-combination of panitumumab and CRT nor for panitumumab
concomitant to RT versus cisplatin-based-CRT [77,78]. In order to explain these negative results,
additional mechanisms of the cetuximab-mediated cytotoxicity have been proposed: besides inhibition
of oncogenic pathways, cetuximab exerts its therapeutic activity by means of induction of an antibody
dependent cell-mediated cytotoxicity [79], whereas the fully humanized antibody panitumumab lacks
this feature. Regarding the triple combination of EGFR-inhibitors, RT and chemotherapy, cetuximab,
which induces a G1 arrest [80] improves efficacy of RT against rapidly repopulating tumor cells during
fractionated irradiation. However, this phenomenon may hamper the efficiency of the combination of
RT and chemotherapy. For example, cisplatin exerts its radiosensitizing potential in proliferating cells,
i.e., in the S/G2/M cell-cycle phases.
Furthermore, various efforts to directly inhibit the kinase domain of EGFR by small molecule
inhibitors erlotinib and gefitinib also failed to improve results. Intriguingly, erlotinib showed
good tolerance and promising results in phase I–II studies, mostly in the recurrent and metastatic
setting [81–85], but also concomitant to RT or re-irradiation with curative intent [86–89]. Nevertheless,
some combinations, e.g. with induction chemotherapy [90], proved to be extremely toxic or not
effective [91] and one of the few randomized trials testing erlotinib in the definitive, curative treatment,
failed to show any benefit when compared to standard CRT [92]. Gefitinib was tested in large, phase
III randomized trials either as monotherapy compared to methotrexate [93] or as doublet together with
docetaxel versus docetaxel plus placebo [94], with both studies revealing negative results. These data
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have stemmed optimism emerging from early phase II trials showing encouraging survival and tumor
control rates for R/M diseases [95]. Additionally, Gregoire et al. were the first to demonstrate negative
results, later confirmed by Ang et al. for cetuximab [96], and Mesia et al. for panitumumab [77] through
triple-combination of gefitinib, cisplatin and RT [97]. Finally, combination of RT and gefitinib with
paclitaxel seems to be toxic and not efficient [98,99]. In accordance with that, a randomized prospective
trial on lapatinib, a novel EGFR/ErbB2-inhibitor approved for treating Her-2-positive breast cancer,
also failed to demonstrate any benefit as concurrence and as maintenance to postoperative CRT in the
curative setting [100].
Afatinib, a next generation irreversible EGFR-tyrosine kinase inhibitor, could have a place in
SCCHN-treatment, at least in the second-line setting for metastatic patients. The “LUX-Head & Neck
1” study was a randomized phase III trial, demonstrating significantly improved PFS after afatinib
when compared to methotrexate for this patient collective, although the median PFS was only 2.6 vs.
1.7 months for experimental and standard arm respectively, which makes the clinical impact of this
result questionable (HR 0.80, 95% CI, 0.65–0.98, p = 0.030) [101]. By contrast, this seems not to be the
case for the curative setting, when afatinib was used adjuvant to CRT in the “LUX-Head & Neck 2”
and “LUX-Head & Neck 4” trials, which both have been terminated prematurely, due to not achieving
the primary endpoint of improving disease free survival [102].
Unfortunately, more than 10 years after the first landmark trials, cetuximab remains the only
targeted agent approved for the treatment of SCCHN. The future of cetuximab in SCCHN-treatment
has been challenged recently, as the first phase III randomized trials indicating its inferiority compared
to cisplatin even for the prognostically favorable HPV-positive-oropharyngeal cancer population were
recently published [103,104]. Other recent efforts to implement cetuximab in more complex regimens,
e.g. as a triplet simultaneous with CRT [96], or concomitant to RT after induction therapy [105] also
failed to show any benefit compared to standard CRT. Thus, considering the improved outcome of
immunotherapy, also in the palliative setting [14], it is likely that EGFR-inhibition will have a different
role in the management of this disease in the near future. Possible new applications for cetuximab could
be a combination with immunotherapy, as it demonstrates strong immunomodulatory effects [79],
but also as second line treatment after failure of checkpoint inhibitors. Prospective trials for both
indications are currently on the way [59] or could demonstrate the first encouraging results [106].
3.3. Targeted Therapies beyond EGFR-Inhibition
As EGFR-inhibition offered only marginal improvement of patient prognosis, the exploration
of targeting alternative pathways was intensified. To this end, the best investigated target-pathway
includes downstream effectors of the phosphatidylinositol-3-kinase PI3K/Akt/mammalian target of
rapamycin signaling cascade, or shortly mTOR-pathway [107]. In 2017, Soulieres et al. published the
results of the prospective, phase II, BERIL-1 trial, which indicated a significant improvement in terms
of PFS and promising OS for the combination of paclitaxel and buparlisib, a PI3K-inhibitor compared
with paclitaxel and placebo in the second line treatment of R/M disease [108]. Several trials utilizing
mTOR-inhibitors like everolimus and temsirolimus have been conducted or are currently recruiting
patients. Yet, most of the results so far are discouraging. In 2015, Massarelli et al. failed to demonstrate
any benefit for the combination of everolimus and erlotinib, and Bauman et al. for temsirolimus and
erlotinib for patients with R/M SCCHN [91,109]. The same holds true in another phase II trial, published
for everolimus monotherapy [110], as well as for a simultaneous EGFR- and PI3K/mTOR-inhibition [111].
However, according to preclinical studies, mTOR-inhibition might manifest its full potential in
combined regimen as shown by an enhancement of the effects of cytostatics like taxanes both in vitro
and in vivo [112]. Indeed, a trial investigating such a combination of temsirolimus with carboplatin
and paclitaxel showed manageable toxicity and considerable efficacy [113].
A phase II study implementing a similar combination-approach, without patient selection, failed
to improve response rate or survival [111]. Thus, a careful selection of patients to benefit from similar
strategies, by implementing novel predictive markers, could be of additional use [114]. This search is
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ongoing and even positive trials like the TEMHEAD-study of the German SCCHN-study group, a
study investigating the effect of temsirolimus in platin- and cetuximab refractory patients, could not
identify any reliable molecular predictive factors [115].
In summary, mTOR-inhibition does not show a clinical activity but is mostly well tolerated [116,117],
even in combination with RT [118]. A recent study could also prove the down-regulation of down-stream
signaling associated with clinical response following rapamycin application in the clinical setting [119].
Nevertheless, response rates remain modest and the optimal clinical setting and combination regimen
remain to be established. An overview of current trials introducing different mTOR-inhibitors for
SCCHN-treatment is depicted in Table 3.
Table 3. Overview of selected trials introducing mTOR inhibitors for head and neck cancer.
Author/
Trial/
NCT Number
Phase No. ofPatients Setting Regimen Endpoint Status
GERCOR
NCT01333085 I/II 49 Curative-LA
Induction with Everolimus,
Carboplatin, Paclitaxel followed
by RT or surgery
I: MTD
II: ORR
Completed
No results
Saba et al. [116]
NCT01283334 I/II 20
Palliative,
1st line
Carboplatin, Cetuximab,
Everolimus
I: MTD
II: PFS
MTD: 2.5 mg every
other day, median
PFS: 8.15 month
NCT01009346 I/II 9 Palliative,1st line
Everolimus, Cetuximab and
Cisplatin
I: MTD
II: PFS
Terminated due to
toxicity
Villaflor et al. [120]
NCT01133678 I/II 94 Curative-LA
Induction Cisplatin, Paclitaxel,
Cetuximab, Everolimus, followed
by reduced-field RT
Tumor response
rate
No benefit of
everolimus
Massarelli et al. [91]
NCT00942734 II 49
Palliative,
2nd line Everolimus, Erlotinib
Tumor response
rate No benefit
NCT01016769 I/II 48 Palliative,1st line
Temsirolimus, Paclitaxel,
Carboplatin
I: dose finding
II: ORR
Completed
Results pending
TEMHEAD,
Grünwald et al. [115]
NCT01172769
II 40 Palliative,1st/2nd line Temsirolimus PFS
Median PFS: 56 d
Median OS: 152 d
Seiwert et al. [121]
MAESTRO HN
NCT01256385
II 86 Palliative2nd line
Temsirolimus +/− Cetuximab
(arms A vs. B) PFS
Median PFS: 105 d
in both arms
4-m-PFS: 41.3 vs
36.4%
Geiger et al. [110]
NCT01051791 II 13
Palliative
1st line Everolimus 10 mg/d CBR
Terminated 28%;
PFS: 1.5 mo, OS: 4.5
month
NCT01195922 II 37, only 16treated Curative-LA Rapamycin (sirolimus)→ surgery
%change in
levels of pS6,
pAKt473, Ki-67
Completed, no
oncological results
NCT01015664 I/II 11 Palliative,1st line
Cisplatin, Cetuximab,
Temsirolimus
I: MTD
II: PFS Terminated
Abbreviations: LA—Locally advanced, RT—Radiotherapy, ORR—Objective response rate, MTD—Maximum
tolerated dose, moMonths, d—Days, OS—Overall survival, PFS—Progression free survival, CBR—Clinical benefit
rate (complete response, partial response, stable disease), GERCOR—Groupe Coopérateur Multidisciplinaire
en Oncologie.
Another targeted agent approved for the treatment of various solid malignancies like ovarian
cancer and cervical cancer [122,123] is bevacizumab, an antibody targeting the vascular endothelial
growth factor (VEGF). Up to date, predominately phase I-II data for this approach in head and neck
cancer were published. In 2013, Holsinger et al. reported, that of five patients treated with temsirolimus
with palliative intent, only the three who received concomitant bevacizumab showed objective response.
This can be attributed either exclusively to the VEGF inhibition or to a synergistic anti-angiogenetic
mechanism, as mTOR-targeting also attenuates the hypoxia-inducible factor HIF-1a [124]. Similar
results have been observed in 46 patients treated with bevacizumab and erlotinib [83].
It is still not clear, if bevacizumab monotherapy is effective in the management of advanced or
metastasized SCCHN and some authors report on enhanced toxicity after combination regimens with
this agent: in a phase I trial evaluating the combination of bevacizumab with cisplatin, erlotinib and
radiation, severe toxicity resulted in a study withdrawal [90] and the agent also seemed to enhance
toxicity both in a phase II study investigating a non-platinum-based combination [125] and the rates
of osteoradionecrosis in another publication [126]. Also, trials investigating the implementation of
bevacizumab-combination regimens for recurrent and poor-prognosis SCCHN showed considerable
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and often unexpected toxicity [127]. However, other studies demonstrated acceptable rates of side
effects when bevacizumab was applied together with intensity-modulated radiotherapy and carefully
dosed cisplatin or cetuximab for patients with stages III-IV disease [125,128–130]. Accordingly, the
feasibility of such treatments remains unclear as only one large phase III trial was completed [131].
In this trial, the addition of bevacizumab to a standard platinum doublet improved response rate and
progression free survival, but not overall survival. Furthermore, severe bleeding-events were more
common in the experimental arm. As anti-VEGF targeting enhances radiation response in preclinical
models [132] and prospective data from a nasopharyngeal-carcinoma therapy [133] are also promising,
further research seems justified. Selected running trials with bevacizumab are summarized in Table 4.
Finally, treatment with other multikinase-inhibitors, that have a proven anti-angiogenetic
component, like sorafenib and sunitinib did not provide any substantial response or prolongation
of survival in various phase II-studies [82,134–136], which led to a stepwise abandonment of further
investigation with this substance class. Yet, Adkins et al. recently demonstrated a safe application
and promising response rates for the combination of cetuximab with the new generation-angiogenesis
inhibitor pazopanib in a phase Ib trial [137].
Table 4. Selected trials implementing VEGF-inhibition by bevacizumab.
Author/Trial/NCT
Number Phase No. of Patients Setting Regimen Endpoint Status
Argiris et al. [138]
NCT00409565 II 46
Palliative, 1 st/2
nd line
Bevacizumab (15 mg/kg, q21)
and Cetuximab ORR
ORR: 16% Median PFS:
2.8 mo
NCT00203905 II 23/30 Curative-LA CRT+FHX +/− Bevacizumab,randomized PFS Completed, no results
Fury et al. [129]
NCT00423930 II 44 Curative-LA IMRT + Cisplatin + Bevacizumab 2y-PFS
2-y-PFS: 75.9; 2-y-OS:
88%
Yao et al. [125]
NCT00281840 I/II 30 Curative-LA
RT + weekly docetaxel
20 mg/qm+ Bevacizumab
(5mg/kg biweekly)
Time to
progression
3-y-PFS: 61.7%; 25/30
not completed
Argiris et al. [139]
NCT00703976 II 80 Curative-LA
RT + Cetuximab + Pemetrexed
+/− Bevacizumab (15 mg/kg, q21)
randomized
2y-PFS 2y-PFS: 79% vs. 75%;2y-OS: 91% vs. 87%
Argiris et al. [140]
NCT00222729 II 42
Palliative, 1 st/2
nd line
Pemetrexed + Bevacizumab
(15 mg/kg, q21)
Time to
progression
Time to progression 5
mo; ORR: 30%
Cohen et al. [83]
NCT00055913 I/II 58
Palliative, 1 st/2
nd line Erlotinib + Bevacizumab (q21)
I: MTD; II:
ORR
15 mg/kg, q21 ORR:
15.2%
Yoo et al. [126]
NCT00140556 I 28 Curative-LA
Induction Bevacizumab +
Erlotinib followed by CRT with
Cisplatin, Bevacizumab +
Erlotinib
Tumor
resolution 25/26 patients
Hainsworth et al.
[141] NCT00392704 II 60 Curative-LA
Induction Carboplatin, Paclitaxel,
Bevacizumab (15 mg/kg, d 1+22)
followed by CRT with Paclitaxel,
Erlotinib, Bevacizumab
(15 mg/kg, d 50+71)
2y-PFS 2y-PFS: 83%
ATHENA
NCT03818061 II Estimated 110
Palliative,
1st line
Bevacizumab (15 mg/kg, q21) +
Atezolizumab ORR Not yet recruiting
NCT00392665 II 36/82 Palliative, 1 st/2nd line
Bevacizumab + Erlotinib vs.
Sulindac + Erlotinib randomized PFS
9.38 vs 7.01 mo
terminated due to
slow accrual
Abbreviations: ORR—Overall response rate, PFS—Progression free survival, mo—Months, CRT—Chemoradiotherapy,
FHX—5-fluorouracil + hydroxyurea, MTD—Maximum tolerated dose.
4. Conclusions
In summary, after an initial euphoria following approval of cetuximab as the first targeted agent for
SCCHN almost 15 years ago, following advances in the field were disappointing and rare, but this may
change by the advent of immunotherapy. As we have learned from the examples of EGFR-inhibition,
similar agents do not necessarily show comparable results and less is sometimes more, as not every
combination could fulfill the expectations. For example, the triple therapy consisting of radiotherapy,
chemotherapy and cetuximab was not better than standard CRT and the same holds true when both PD-1
and CTLA-4 were targeted compared to anti-PD-1 monotherapy. Although current research [142,143]
indicates the superiority of combined modality, every step should be undertaken carefully in order to
avoid ineffective or toxic approaches. In times of personalized medicine, we should abandon “one size
fits all” concepts, but rather address selected populations, based on both clinical features like elderly,
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frail, oligometastatic and molecular prognosticators/accurate biomarkers. Alternative strategies, that
have yet to be studied in depth, both in terms of immune system modulation (like NK cell inhibitors,
alternative checkpoints, adoptive T-cell therapies, vaccine approaches, etc.) and new molecular targets
(e.g., CKD: cyclin depended kinase, WEE1 kinase) should also be considered [144,145]. At the same
time, “traditional” treatments with proven efficacy like radiotherapy and chemotherapy should be
integrated, as they open new possibilities, enhance the therapeutic spectrum of novel agents and could
easily be combined with innovative technologies like nanoparticular drug transport [146]. Finally, RT
demonstrates immunosensitizing effects and checkpoint-inhibition impacts on radiation sensitivity [10],
however the best dose and fractionating schedule for combined approaches remains elusive. Thus,
the future is challenging as systemic treatment for head and neck cancer remains the cutting edge of
modern oncological research.
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